Pharmaceuticals: Roche acquires AI specialist PathAI | blue News

Roche is expanding in the field of digital pathology. An agreement has been reached to acquire the US company PathAI. Pathological images are analyzed and evaluated using artificial intelligence. With this acquisition, the pharmaceutical company aims to expand its position in AI-based diagnostic solutions. The purchase price is 750 million US dollars plus possible milestone payments of up to 300 million US dollars, as the company announced on Thursday. The combination of PathAI's AI-powered Image Management System (IMS) with Roche's diagnostic capabilities is expected to increase the efficiency of laboratories, accelerate the development of new clinical therapies and enable the discovery of new biomarkers and new diagnostic tools. Roche expects this to be a further step towards personalized medicine. Roche and PathAI already entered into a collaboration in 2021, which was intensified in 2024. Roche expects the acquisition of PathAI to be completed in the second half of the current year, provided the usual regulatory and competition law conditions are met. If the transaction is completed, Roche intends to integrate PathAI into its own diagnostics division.